Immuneering Corporation (IMRX) saw a significant price increase today, closing at $1.84, up 13.58% from the previous close of $1.62. The stock opened at $1.60 and reached an intraday high of $1.86, with trading volume at 508,360 shares, which is 31.05% of the average volume. The upward movement was primarily driven by the announcement of the launch of its Pancreatic Cancer Advisory Board. This development highlights the clinical progress of their lead candidate, IMM-1-104, which has received Orphan Drug and Fast Track designations for pancreatic cancer treatments. The advisory board, comprising renowned oncology researchers, is expected to provide strategic guidance as the company advances its pipeline. This news has likely bolstered investor confidence, contributing to the stock's rise.